The federal government could provide higher reimbursement for new antibiotics as a way to incentivize companies to develop new therapies, the President’s Council of Advisors on Science and Technology (PCAST) recommends in its report on combatting antibiotic resistance.
PCAST offers several other suggestions for boosting commercial development, including that the government subsidize R&D programs for antibiotics; provide companies with a financial reward, such as a one-time lump payment,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?